Search results
Jul 29, 2024 · Hummingbird Bioscience is a biotech company developing next-generation antibody-based therapies for cancer, using proprietary linker-payload technologies. Learn more about their pipeline, precision biology, and clinical trials.
- About Us
We are a clinical-stage biotechnology company with a...
- Pipeline
Hummingbird Bioscience Programs Target Class Discovery...
- News & Publications
Hummingbird Bioscience, a data-driven precision...
- Careers
Hummingbird Bioscience is a great environment for learning...
- HMBD-001
Developed with our Rational Antibody Discovery platform,...
- About Us (preview)
We are a clinical-stage biotechnology company with a...
- ADC Platform
Hummingbird Bioscience is developing a 4 th generation ADC...
- Antibody Platform
Hummingbird’s Rational Antibody Discovery platform leverages...
- About Us
Hummingbird Bioscience is a biotech company with a Rational Antibody Discovery platform, developing precision therapeutics for cancer and autoimmune disease. Learn about their team, vision, and pipeline of novel drugs.
Hummingbird Bioscience develops novel, precision therapeutics for cancer and autoimmune disease using a proprietary Rational Antibody Discovery platform. Learn about the company's founders, management, board of directors and scientific advisors.
Hummingbird Bioscience is a Singapore-based biotech company developing biologic medicines for hard-to-treat diseases. Learn about its history, locations, employees, updates, and achievements on LinkedIn.
- 107
Hummingbird Bioscience is a Singapore-based biotech company developing biologic medicines for hard-to-treat diseases. Learn about its history, locations, employees, updates, and achievements on LinkedIn.
May 18, 2021 · CLINICAL-STAGE biotech outfit Hummingbird Bioscience has raised US$125 million in a Series C round led by life science investor Novo Holdings, the startup announced on Tuesday.
Sep 13, 2021 · Hummingbird Bioscience announced US FDA clearance of IND for HMBD-002, a first-in-class anti-VISTA neutralizing antibody for advanced solid tumors. HMBD-002 is a rationally engineered IgG4 antibody that blocks VISTA-mediated immune suppression and shows synergy with PD-1 inhibitor.
